

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Results from the REFLECT trial (Study 304) for patients with unresectable HCC in the first-line setting reported _____ with lenvatinib versus sorafenib.
 - a. Superiority in overall survival (OS)
 - b. Significant improvement in progression-free survival (PFS)
 - c. Significant benefit in response rate
 - d. All of the above
 - e. Both b and c
2. Results of studies evaluating the antitumor activity of checkpoint inhibitors in patients with HCC have demonstrated _____.
 - a. An overall response rate (ORR) of 15% to 20% as first-line therapy
 - b. Responses in only those patients with high tumor mutational burdens
 - c. Both a and b
 - d. Neither a nor b
3. Which of the following is true regarding the Phase III CELESTIAL trial evaluating cabozantinib versus placebo for patients with advanced HCC previously treated with sorafenib?
 - a. A significant improvement in OS was reported in the cabozantinib arm
 - b. No dose reductions were required in the cabozantinib arm
 - c. Both a and b
 - d. Neither a nor b
4. The ongoing CheckMate 459 trial is evaluating sorafenib versus nivolumab for patients with advanced HCC in which setting?
 - a. First line
 - b. Second line
 - c. Late line
5. What did the SIRveNIB study comparing SIRT to sorafenib for locally advanced HCC demonstrate in terms of OS?
 - a. Significant improvement with sorafenib
 - b. Significant improvement with SIRT
 - c. No significant difference between the 2 arms
6. Preliminary results from a Phase I study presented by Finn and colleagues at ASCO 2018 demonstrated an ORR of approximately 40% with lenvatinib/pembrolizumab for patients with unresectable HCC.
 - a. True
 - b. False
7. The Phase III REACH-2 trial presented at ASCO 2018 by Zhu and colleagues demonstrated a significant improvement in OS with ramucirumab versus placebo as second-line therapy for patients with advanced HCC and high _____.
 - a. AFP
 - b. VEGFR expression
 - c. Tumor burden
8. Which of the following is true regarding the Phase III RESORCE trial evaluating regorafenib versus placebo for patients with HCC with disease progression on sorafenib?
 - a. A significant improvement in OS was observed with regorafenib
 - b. A significant improvement in PFS was observed with regorafenib
 - c. Both a and b
 - d. Neither a nor b
9. The ongoing Phase III HIMALAYA study is investigating _____ in combination with tremelimumab as first-line treatment for unresectable HCC.
 - a. Pembrolizumab
 - b. Durvalumab
 - c. Nivolumab
10. Which of the following is true regarding the safety profile of lenvatinib in HCC?
 - a. Lenvatinib is associated with a higher incidence of hypertension than is sorafenib
 - b. Lenvatinib is associated with a higher incidence of hand-foot skin reaction than is sorafenib
 - c. Hepatic function should be monitored
 - d. All of the above
 - e. Both a and c